Business Context and Reporting Period
This Form 8-K reports on the results of the 2025 Annual Meeting of Stockholders held by Gyre Therapeutics, Inc. on June 4, 2025. The record date for the meeting was April 10, 2025, with 93,742,602 shares of common stock entitled to vote.
Key Financial Metrics
This filing is a current report regarding corporate governance and voting results. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data.
Material Changes
No material financial changes are reported in this document. The filing details the successful election of director nominees and the approval of executive compensation and auditor ratification.
Guidance, Outlook, and Voting Results
The filing provides the final voting results for three proposals:
- Proposal 1: Election of Directors - All Class I nominees were elected to serve until the 2028 Annual Meeting:
- Gordon Carmichael, Ph.D.: 69,249,334 votes for; 297,881 withheld.
- Songjiang Ma: 69,385,506 votes for; 161,709 withheld.
- Ping Zhang: 69,320,687 votes for; 226,528 withheld.
- Proposal 2: Non-Binding Advisory Vote on Executive Compensation - Approved with 69,505,961 votes for, 39,318 against, and 1,936 abstentions.
- Proposal 3: Ratification of Independent Auditor - Grant Thornton Zhitong Certified Public Accountants LLP was ratified for the year ending December 31, 2025, with 72,175,754 votes for, 3,738 against, and 146,263 abstentions.
The filing does not provide management commentary on future guidance, risks, or contingencies beyond the standard disclosure of voting outcomes.
Investor Verification Checklist
- Verify the definitive proxy statement filed on April 21, 2025, for detailed background on the director nominees and executive compensation.
- Confirm the appointment of Grant Thornton Zhitong Certified Public Accountants LLP as the independent auditor for the 2025 fiscal year.
- Note that 2,778,540 broker non-votes were recorded for the director election and executive compensation proposals.